Circulating tumor cells predict survival in patients with metastatic prostate cancer

Urology

Volumn 65, Issue 4, 2005, Pages 713-718

  Moreno, Jose G ^b   Miller, M Craig ^b   Gross, Steve ^b   Allard, W Jeffrey ^b   Gomella, Leonard G ^b   Terstappen, Leon W M M ^a  

^a Immunicon Corporation   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CD45 ANTIGEN; CYTOKERATIN; EPITHELIAL CELL ADHESION MOLECULE; NANOPARTICLE; NUCLEIC ACID;

AGED; ANALYTIC METHOD; ARTICLE; BLOOD ANALYSIS; BLOOD SAMPLING; CANCER SURVIVAL; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; EVALUATION; FLOW CYTOMETRY; FLUORESCENCE; HUMAN; LIGHT SCATTERING; MALE; PREDICTION; PRIORITY JOURNAL; PROSTATE CANCER; TARGET CELL; TUMOR CELL;

EID: 17144426134     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.urology.2004.11.006     Document Type: Article

References (23)

1. E.D. Crawford Epidemiology of prostate cancer Urology 62 2003 3 12
2. C.R. Pound, A.W. Partin, M.A. Eisenberger Natural history of progression to metastases and death from prostate cancer in men with PSA recurrence following radical prostatectomy JAMA 281 1999 1591 1597
3. G.J. Bubley, M. Carducci, W. Dahut Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer recommendations from the Prostate-Specific Antigen Working Group J Clin Oncol 11 1999 3461 3467
4. S. Halabi, E.J. Small, P.W. Kantoff Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer J Clin Oncol 21 2003 1232 1237
5. M.J. Shulman, E.A. Benaim The natural history of androgen independent prostate cancer J Urol 172 2004 141 145
6. M.J. Shulman, J.A. Karam, E.A. Benaim Prostate-specific antigen doubling time predicts response to deferred antiandrogen therapy in men with androgen-independent prostate cancer Urology 63 2004 732 736
7. A.V. D'Amico, K. Cote, M. Loffredo Determinants of prostate cancer specific survival following radiation therapy during the prostate specific antigen era J Urol 170 2003 S42 S47
8. A.V. D'Amico, J.W. Moul, P.R. Carroll Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy J Natl Cancer Inst 95 2003 1376 1383
9. R.D. Loberg, J.R. Fielhauer, B.A. Pienta Prostate-specific antigen doubling time and survival in patients with advanced metastatic prostate cancer Urology 62 suppl 1 2003 128 133
10. J.W. Moul Variables in predicting survival based on treating "PSA-only" relapse Urol Oncol 21 2003 292 304
11. H.P. Schmid, R. Morant, J. Bernhard Swiss Group for Clinical Cancer Research (SAKK) Prostate specific antigen doubling time as auxiliary end point in hormone refractory prostatic carcinoma Eur Urol 43 2003 28 30
12. H.P. Schmid, J. Bernhard, A. Semjonow Prostate specific antigen in as a dynamic model in advanced prostate cancer Anticancer Res 20 2000 4985 4987
13. J.G. Moreno, C.M. Croce, R. Fischer Detection of hematogenous micrometastasis in patients with prostate cancer Cancer Res 52 1992 6110 6112
14. S. Halabi, E.J. Small, D.F. Hayes Prognostic significance of reverse transcriptase polymerase chain reaction for prostate-specific antigen in metastatic prostate cancer a nested study within CALBG 9583 J Clin Oncol 21 2003 490 495
15. P.O. Ts'o, J. Pannek, Z.P. Wang Detection of intact prostate cancer cells in the blood of men with prostate cancer Urology 49 1997 881 885
16. T.J. Polascik, Z.P. Wang, M. Shue Influence of sextant prostate needle biopsy or surgery on the detection and harvest of intact circulating prostate cancer cells J Urol 162 1999 749 752
17. Z.P. Wang, M.A. Eisenberger, M.A. Carducci Identification and characterization of circulating prostate carcinoma cells Cancer 88 2000 2787 2795
18. J.G. Moreno, S.M. O'Hara, S. Gross Changes in circulating carcinoma cells in metastatic prostate cancer patients correlates with disease status Urology 58 2001 386 392
19. M. Cristofanilli, G.T. Budd, M.J. Ellis Circulating tumor cells, disease progression and survival in metastatic breast cancer N Engl J Med 351 2004 781 791
20. T. Fehm, A. Sagalowsky, E. Clifford Cytogenetic evidence that circulating epithelial cells in patients with carcinoma are malignant Clin Cancer Res 8 2002 2073 2084
21. W.K. Kelly, H.I. Sher, M. Mazumdar Prostate-specific antigen as measure of disease outcome in metastatic hormone refractory prostate cancer J Clin Oncol 11 1993 607 615
22. D.F. Hayes, T.M. Walker, B. Singh Monitoring expression of HER-2 on circulating epithelial cells in patients with advanced breast cancer Int J Oncol 21 2002 1111 1118
23. S.M. O'Hara, J.G. Moreno, D.R. Zweitzig Multigene reverse transcription-PCR profiling of circulating tumor cells in hormone-refractory prostate cancer Clin Chem 50 2004 826 835